IntegraGen: Lower Results, Reduced Expenses in the First Half of 2025

IntegraGen, a company specializing in cancer genomics, announced a decline in its results for the first half of 2025. Revenues totaled €2.749 million, marking a 43% decrease compared to 2024. This decline was exacerbated by the absence of non-recurring revenue from the SeqOIA contract. Operating expenses were reduced by 20%, thanks to a cost-cutting plan that included reductions in raw materials and payroll.

Net income showed a loss of €1.407 million, a significant worsening compared to 2024. However, cash reserves remained relatively stable at €1.721 million. IntegraGen is now focusing on its operational efficiency, supported by its CLIA/CAP certification, to assist the clinical development of its pharmaceutical partners.